ProQR Therapeutics N.V.
PRQR$158M
Micro CapNASDAQBiotechnology🇺🇸North America166 employees
Drugs in Pipeline
4
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
PRQR News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
sepofarsen
Leber Congenital Amaurosis 10
QR-1123
Autosomal Dominant Retinitis Pigmentosa
QR-421a
Retinitis Pigmentosa
QR-010
Cystic Fibrosis
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
sepofarsen | Phase 3 | Leber Congenital Amaurosis 10 | - |
QR-1123 | Phase 2 | Autosomal Dominant Retinitis Pigmentosa | - |
QR-421a | Phase 2 | Retinitis Pigmentosa | - |
QR-010 | Phase 2 | Cystic Fibrosis | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply